Rinvoq ER 45 MG tablet UU 28S
Ended Awarded
- Contract number
- SPE2DB25FX28A
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $39,491
Award facts
- Contract value 100% obligated
- $39,491.47 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $39,491.47 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026 that enables the company to supply a comprehensive range of medications and medical supplies to support military healthcare programs worldwide.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical federal medical procurement vendor primarily through its relationship with the Defense Logistics Agency and its Medical Supply Chain. The company's extensive federal contract portfolio demonstrates competency in delivering brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support Defense Health Agency and other government healthcare systems. RINVOQ ER (upadacitinib extended-release) is a Janus kinase inhibitor used in the treatment of rheumatoid arthritis and other immune-mediated inflammatory diseases, representing the type of specialty pharmaceutical product that supports military and veteran healthcare requirements.
Quick answers
Who was awarded contract SPE2DB25FX28A?
SPE2DB25FX28A was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on August 8, 2025.
How much is contract SPE2DB25FX28A worth?
The government has obligated $39,491 on SPE2DB25FX28A.
Is contract SPE2DB25FX28A an order under another contract?
Yes. SPE2DB25FX28A is a delivery order under SPE2DB20D2200, an indefinite delivery contract.
Was contract SPE2DB25FX28A competed?
The extent of competition for SPE2DB25FX28A was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award